Abiomed, Inc. (Nasdaq: ABMD) announced it has expanded its U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for Impella ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE